logo
Plus   Neg
Share
Email

Cerus Announces Inactivation Of SARS-CoV-2 With INTERCEPT Blood System For Plasma

Cerus Corp. (CERS) announced successful inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma.

The data are consistent with prior INTERCEPT studies showing complete inactivation, to below the limit of detection, of other coronaviruses associated with severe pulmonary disease: MERS-CoV1,2 (2018, 2019) and SARS-CoV-13 (2005).

In Tuesday pre-market trade, CERS is trading at $7.66, up $0.80 or 11.66 percent.

The in vitro study evaluated inactivation of SARS-CoV-2 in plasma components using both infection and molecular assays, as well as cell culture passaging experiments, allowing the confirmation of complete inactivation over time.

The investigators are currently conducting a subsequent study to assess the ability of the INTERCEPT Blood System to inactivate SARS-CoV-2 in platelet components. The studies are funded by the Saudi Arabia Ministry of Health and supported by Cerus.

Separately, Cerus is conducting a set of in vitro studies in the United States to assess the INTERCEPT Blood System's ability to inactivate SARS-CoV-2 in red blood cells, as well as platelets and plasma. The studies are funded by the Biomedical Advanced Research and Development Authority as part of Cerus' recent contract amendment and associated funding increase.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
H-E-B has issued an all-store recall for Blue Cheese Salmon Burgers citing the presence of an undeclared allergen, the U.S. Food and Drug Administration announced. The products contain wheat, a known allergen, which is not declared on the product label. Consumers with allergy or severe sensitivity to wheat may get serious or life-threatening allergic reaction if they consume these products. The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter. The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases.
RELATED NEWS
Follow RTT